新华制药：获得缬沙坦胶囊、间苯三酚注射液药品注册证书

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the registration certificates of Valsartan capsules and Isosorbide Injection, indicating a significant advancement in its product offerings and potential market expansion [1] Group 1: Product Approvals - Valsartan capsules are indicated for the treatment of mild to moderate primary hypertension [1] - Isosorbide Injection is used for treating acute spasmodic pain caused by digestive system and biliary dysfunction, acute spasmodic urethral, bladder, and renal colic, as well as gynecological spasmodic pain [1]